Wednesday, 7 October 2015

Cannabis - All Research

A very big thank you to Matt Aldridge for putting this information together

Please Support #EndOurPain for legal access to cannabis as a medicine.

Scientific Studies from the National Institute of Health

If you’re still in doubt regarding the potential of cannabis in the treatment of cancer, have a look at these 100+ scientific studies from the National Institute of Health:
Cannabis kills tumour cells
Uterine, testicular, and pancreatic cancers
Brain cancer
Mouth and throat cancer
Breast cancer
Lung cancer
Prostate cancer
Blood cancer
Skin cancer
Liver cancer
Cannabis and cancer (general)
Cancers of the head and neck
Cholangiocarcinoma cancer
Cannabis partially/fully induced cancer cell death
Translocation-positive rhabdomyosarcoma
Cannabis kills cancer cells
Thyroid carcinoma
Colon cancer
Intestinal inflammation and cancer
Cannabinoids in health and disease
Cannabis inhibits cancer cell invasion
Pharmacokinetics and pharmacodynamics of cannabinoids.
Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.
Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.
Cannabinoid receptors in human astroglial tumors.
Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells.
Antitumorigenic effects of cannabinoids beyond apoptosis.
R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells.
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
Cannabinoids in health and disease.
Cannabinoids and cancer.
Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.
Endocannabinoids in the immune system and cancer.
A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis.
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
Cannabinoids as potential new therapy for the treatment of gliomas.
The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells.
Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).
Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.
[The endocannabinoid system as a target for the development of new drugs for cancer therapy].
Cannabinoids in intestinal inflammation and cancer.
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.
The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation.
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines.
Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders.
Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines.
Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells.
Cannabinoids in the treatment of cancer.
Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein.
Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma.
[Different views on the association between cannabinoids and cancer].
De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis.
Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.
JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
Cannabinoid receptors as novel targets for the treatment of melanoma.
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.
Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development.
Cannabinoids and ceramide: two lipids acting hand-by-hand.
p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells.
The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway.
The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.
Control of the cell survival/death decision by cannabinoids.
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas.
Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Cannabinoids and gliomas.
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.
Effects on cell viability.
Involvement of cannabinoids in cellular proliferation.
Hypothesis: cannabinoid therapy for the treatment of gliomas?
Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway.
Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.
Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.
Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.
Cannabinoids and cell fate.
Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis.
Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.
Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma.
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation.
Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1.
Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?
Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.
Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma.
Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells.
The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration.
Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers?
Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway.
The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death.
High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells.
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Cannabinoids as novel anti-inflammatory drugs.
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.
In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas.
Cannabinoid receptor as a novel target for the treatment of prostate cancer.
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
Cannabinoids for cancer treatment: progress and promise.
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.
Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.
Cannabinoids and the immune system.
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.
The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.
Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells.

Jon Liebling – Political Director of United Patients Alliance
Join us/Follow Us/Like Us/Help Us.

No comments:

Post a Comment